The antibody cut new abnormal bone formation by up to 90% in a trial for fibrodysplasia ossificans progressiva — a devastating disorder in which soft tissue slowly turns to bone.
Vitestro’s Aletta autonomously finds a vein and draws blood in adults, with one trained phlebotomist supervising up to three machines — a possible answer to a worsening staffing shortage.
An observational analysis of more than 31,000 patients tied one widely used class of blood-pressure pills to a 33% higher risk of serious kidney events — though researchers stress it cannot prove cause.
In the Phase 3 SAFFRON trial, adding Hutchmed’s Orpathys to Tagrisso delayed progression and extended overall survival in EGFR-mutated lung cancer that had developed a MET-driven resistance.
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.
While the industry chases GLP-1 agonists for weight loss, Amylyx went the other way — and its GLP-1 antagonist cut severe hypoglycemic events by 55% in a late-stage trial.
PIKTOR, an oral combination that hits the PI3K/AKT/mTOR pathway, won fast-track status alongside chemotherapy for endometrial cancer that has progressed despite prior treatment.
The company’s long-acting retina treatment failed to prove non-inferiority to standard therapy across the full trial, wiping out nearly $1 billion in market value.
The antibody drug improved muscle strength and function in adults with inflammatory muscle disease, setting up a potential label expansion for a therapy already generating billions.
After shelving its sickle cell program over safety concerns, Fulcrum is combining with Slate Medicines in a reverse merger built around a next-generation migraine drug.
Researchers paired live malaria parasites with a drug that stops them in the liver, converting infectious bites into immunizing events that produced durable protection in animals.
By fusing therapeutic antibodies to albumin, researchers cut how much of the drug crosses the placenta — without sacrificing the long-lasting effect that makes these medicines useful.